Corning at ISCT 2022 | International Society for Cell and Gene Therapy Annual Meeting | Corning

ISCT 2022

May 4-7, 2022 | San Francisco, CA | Corning Booth #510

Corning will showcase its solutions for cell culture scale-up from research to production in booth #510 at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting, May 4-7, 2022 in San Francisco, CA.

Featured solutions will include:


  • Corning® Ascent™ Fixed Bed Bioreactor System
  • Adherent workflow solutions including HYPERFlask®, CellSTACK® and HYPERStack® vessels
  • Suspension workflow solutions
  • Microcarrier workflow solutions, including Corning Dissolvable Microcarriers
  • Corning X-Series® Cell Separation Platform
ISCT 2022

Global Showcase Theater Presentations | May 5, Theater 2

TimeTitle & DescriptionPresented ByLocation
2:30 p.m.

Scaling Stem Cell and AAV Production to Manufacturing Scales with a Novel Intensified Adherent Cell Culture System

 

Large scale expansion of anchorage-dependent cells has historically presented many challenges. Through innovation of the attachment substrate and integration with automation capabilities, we can now achieve high vector yield efficiency, viable cell harvest, and automated processing with an adherent platform. Corning Senior Field Applications Scientist Austin Mogen will present the Corning Ascent™ FBR System, a new, intensified fixed bed reactor technology that has demonstrated a multi-fold increase in viral vector yield per cm2, greater than 90% transfection efficiency, and enables high-yield viable cell harvest. This scalable technology can help to reduce time to market, process variability, and overall production costs by enabling a scale-up solution that maintains consistency from process development to manufacturing. 

Austin Mogen, Senior Field Applications ScientistTheater 2
2:45 p.m.

Improve cell processing and advance cell therapy with the Corning® X-SERIES® Cell Separation Platform

 

To bring ground-breaking cell therapies to many patients as quickly as possible, developers and manufacturers need to improve on manual, open, and time-consuming processes. The Corning X-SERIES Cell Separation Platform simplifies the cell therapy workflow by automating many of the necessary steps involved in cell processing. This flexible, multi-system platform provides a streamlined solution for efficient, reliable, and reproducible density gradient media-free recovery of target cell populations from blood and blood products. It provides speed and performance gains in purifying mononuclear cells, washing contaminants from cell fractions, selecting specific cell populations, and concentrating cellular suspensions. The Corning X-SERIES Cell Separation Platform provides a comprehensive and commercially viable, semi-automated manufacturing and controlled solution for the development of cell therapies. 

Tom Bongiorno, Field Applications ScientistTheater 2
share